Challenge and promise: Roles for clusterin in pathogenesis, progression and therapy of cancer

Cell Death and Differentiation

Volumn 13, Issue 1, 2006, Pages 12-19

  Shannan, B ^a   Seifert, M ^a   Leskov, K ^b   Willis, J ^c   Boothman, D ^d   Tilgen, W ^a   Reichrath, J ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Clusterin; DNA repair; Human tumours; nCLU; sCLU

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BXL 628; CALCITRIOL; CALCITRIOL DERIVATIVE; CISPLATIN; CLUSTERIN; CLUSTERIN ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC AGENT; DOUBLE STRANDED RNA; NUCLEAR CLUSTERIN; OGX 011; PACLITAXEL; PROTEIN BCL 2 ANTISENSE OLIGONUCLEOTIDE; SECRETORY CLUSTERIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; UNCLASSIFIED DRUG; CLU PROTEIN, HUMAN; ISOPROTEIN; TUMOR MARKER;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL MEMBRANE; CELL PROTECTION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DNA REPAIR; DRUG POTENTIATION; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; IONIZING RADIATION; KIDNEY CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; ULTRAVIOLET RADIATION; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL CYCLE; CLUSTERIN; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644996125     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401779     Document Type: Review

References (52)

1. Trougakos IP and Gonos ES (2002) Clusterin/apolipoprotein J in human ageing and cancer. Int. J. Biochem. Cell Biol. 34: 1430-1448
2. Trougakso IP, So A, Jansen B, Gleave ME and Gonos ES (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64: 1834-1842
3. Pucci S, Bonanno E, Pichiorri F, Angeloni C and Spagnoli LG (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23: 2298-2304
4. Gleave M and Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23: 38-46
5. Lakins J, Steffany A, Bennett L, Chen JH, Arnold JM, Morrissey C, Wong P, O'Sullivan J and Tenniswood M (1998) Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J. Biol. Chem. 273: 27887-27895
6. Miyake H, Hara I, Kamidono S and Gleave ME (2001) Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7: 4245-4252
7. Hara I, Miyake H, Gleave ME and Kamidono S (2001) Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn. J. Cancer Res. 92: 1220-1224
8. Miyake H, Hara I, Gleave ME and Eto H (2004) Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61: 318-323
9. Miyake H, Nelson C, Rennie PS and Gleave ME (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 60: 170-176
10. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K and Gleave ME (2002) Enhanced radiosensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8: 3276-3284
11. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M and Corti A (2002) Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21: 4328-4334
12. van Weelden K, Flanagan L, Binderup L, Tenniswood M and Welsh JE (1998) Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analogue, EB1089. Endocrinology 139: 2102-2110
13. Leskov KS, Klokov DY, Li J, Kinsella TJ and Boothman DA (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278: 11590-11600
14. July LV, Beraldi E, So A, Fazil L, Evans K, English JC and Gleave ME (2004) Nucleotide-based therapies targeting clusterin chemosensitized human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3: 223-232
15. Jin G and Howe PH (1999) Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur. J. Biochem. 263: 534-542
16. Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C, Kinsella TJ, Chen DJ and Boothman DA (1999) Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27: 2165-2174
17. Criswell T, Klokov D, Beman M, Lavik JP and Boothman DA (2003) Repression of IR-inducible clusterin expression by the p53 tumour suppressor protein. Cancer Biol. Ther. 2: 372-380
18. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K and Gleave ME (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 92: 463-469
19. Miyake H, Hara I, Kamidono S, Gleave ME and Eto H (2003) Resistance to cytotoxc chemotherapy induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol. Rep. 10: 469-4673
20. Osborne JE and Hutchinson PE (2002) Vitamin D and systemic cancer: Is this relevant to malignant melanoma? Br. J. Dermatol. 147: 197-213
21. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B and Sala A (2000) Direct transactivation of the antiapoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275: 21055-21060
22. Sankilli G, Aronow BJ and Sala A (2003) Essential requirements of apolipoprotein J (clusterin) signalling for IκB expression and regulation of NF-κB activity. J. Biol. Chem. 278: 38214-38219
23. Bettuzzi S, Astancolle S, Guidentti G, Moretti M, Tiozzo R and Corti A (1999) Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts. FEBS Lett. 448: 297-300
24. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink J, Kinsella T and Boothman DA (2000) Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Nucleic Acids Res. 97: 5907-5912
25. Leskov K, Criswell T, Antonio S, Li J, Yang CR, Kinsella TJ and Boothman DA (2001) When X-ray-inducible proteins meet DNA double strand break repair. Semin. Radiat. Oncol. 11: 352-372
26. Sawada M, Hayes P and Matsuyama S (2003) Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 5: 352-357
27. Matuda A, Itoh Y, Koshikawa N, Akizawa T, Yana I and Sieki M (2003) Clusterin: An abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J. Biol. Chem. 278: 36350-36357
28. Seiberg M and Marthinuss J (1995) Clusterin expression within skin correlates with hair growth. Dev. Dyn. 202: 294-01
29. Thomas-Salgar S and Millis AJ (1994) Clusterin expression in differentiating smooth muscle cells. J. Biol. Chem. 269: 17879-17885
30. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 42: 31-41
31. 3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 58: 395-401
32. Narvaez CJ, Vanweelden K, Byrne I and Welsh J (1996) Characterization of vitamin D3-resistant MCF-7 cell line. Endocrinology 137: 400-409
33. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E, Adorini L and Maggi M (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 150: 591-603
34. Gutacker C, Klock G, Diel P and Kock-Brabdt C (1999) Nerve growth factor and epidermal growth factor stimulate clusterin gene expression in PC12 cells. Biochem. J. 339: 759-766
35. Wegrowski Y, Perreau C, Martiny L, Haye B, Maquart FX and Bellon C (1999) Transforming growth factor beta-1 up-regulates clusterin synthesis in thyroid epithelial cells. Exp. Cell Res. 247: 475-483
36. Araki S, Leskov K, Klokov D, Kang S-W, Stavnezer E, Danielpour D and Boothman DA (2005) Regulation of the clusterin promoter by TGF-β1 involves Smad3 activation and binding. Mol. Cell. Biol. (submitted)
37. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A and Bettuzzi S (2004) Clusterin (SGP-2, APOJ) expression is downregulated in low- and high-grade human prostate cancer. Int. J. Cancer 108: 23-30
38. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK (2002) Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157: 393-399
39. Chen X, Halberg RB, Ehrhardt WM, Torrealba J and Dover WF (2003) Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. USA 100: 9530-9535
40. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, El-Deiry W, Aronow B, Kaya G, Saurat JH and French LE (2004) Myc-transformed epithelial cells down-regulate clusterin, which inhibits either growth in vitro and carcinogenesis in vivo. Cancer Res. 61: 3126-3136
41. Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K and Zha XH (2003) Loss of clusterin both in serum and tissue correlates with the tumorigenesis of oesophageal squamous cell carcinoma via proteomic approaches. World J Gastroenterol 9: 650-654
42. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F and Sawabu N (2002) Expression of clusterin in human pancreatic cancer. Pancreas 25: 234-238
43. Saffer H, Wahed A, Rassidakis GZ and Medeiros LJ (2002) Clusterin expression in malignant lymphomas. Mod. Pathol. 15: 1221-1223
44. July LV, Akbari M, Zellweger T, Jones EC, Goldenberry SL and Gleave ME (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50: 179-188
45. Biroccio A, D'angel C, Jansen B, Gleave ME and Zupi G (2005) Antisense clusterin oligonucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. J. Cell. Physiol. 204: 463-469
46. Gleave ME and Monia BP (2005) Antisense therapy for cancer. Nat. Rev. Cancer. 5: 468-479
47. Yamanaka K, Gleave ME, Hara I, Muramaki M and Miyake H (2005) Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol. Cancer Ther. 4: 187-195
48. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S and Gleave ME (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3: 360-367
49. Gleave M and Jansen B (2003) Clusterin and IGFBPs as antisense targets in prostate cancer. Ann. NY Acad. Sci. 1002: 95-104
50. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayp LD and Boothman DA (2005) Delayed activation of insulin-like growth factor-1 receptor/ Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem. 280: 14212-14221
51. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP and Gleave ME (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O(2-methoxy) ethyl chemistry. J. Pharmacol. Exp. Ther. 298: 934-940
52. Chung J, Kwak C, Jin RJ, Lee CH, Lee KH and Lee SE (2004) Enhanced chemosensitivity of baldder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett. 203: 155-161